Acumen Pharmaceuticals announced that it has commenced an underwritten public offering of $100M of shares of its common stock. BofA Securities, Citigroup and Stifel are acting as bookrunners for the public offering. BTIG is acting as lead manager for the public offering. Acumen intends to use its net proceeds from the public offering primarily to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, to fund chemistry, manufacturing and other research and development activities, and for working capital and other general corporate purposes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABOS:
- Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Acumen Pharma (NASDAQ:ABOS) Skyrockets on Promising Phase 1 Data in Alzheimer’s Disease
- Acumen holds a conference call
- Acumen to hold conference call on topline results from ACU193 Phase 1 study
- Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease